Thelansis

  Marginal zone lymphoma (MZL) is the second most common indolent non-Hodgkin’s lymphoma (iNHL). There are three types of marginal zone lymphomas: the extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT or gastric GALT), the splenic MZL, and the nodal MZL. The age-standardized incidence rate for MZL is 27.6 per 1,000,000 and was slightly higher in males in comparison with females (19.1). EMZL represents 60.8% of MZLs, followed by NMZL (30.3%) and SMZL (8.9%). The competitive landscape of Marginal zone lymphoma (MZL) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary. KOLs insights of Marginal zone lymphoma (MZL) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unme...